Innovative Drug R&D for Metabolic Diseases Forum

Agendas

14:00 - 17:40
  • 代谢创新研发论坛
  • Innovative Drug R&D for Metabolic Diseases Forum
14:00 - 15:50
  • 第一阶段：共话代谢-临床与市场多维度需求
  • Session I: Conversation in Metabolism - Diverse Clinical and Market Needs
    • Moderator
  • 纪立农 ， 中国药促会糖尿病与代谢性疾病药物临床研究专业委员会主任委员，北京大学人民医院内分泌科主任
  • JI Linong , Chairman of Diabetes and Metabolic Disease Clinical Research Committee of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Director of Endocrinology and Metabolism Department,Peking University People's Hospital
14:00 - 14:30
  • 主题报告1
  • Keynote Speech 1
  • 心血管-肾脏-代谢三联症 新药研发及临床管理思考
  • Reflections on the R&D of New Drugs and Clinical Management of Cardiovascular-Kidney-Metabolic Diseases
  • 纪立农 中国药促会糖尿病与代谢性疾病药物临床研究专业委员会主任委员，北京大学人民医院内分泌科主任
  • JI Linong , Chairman of Diabetes and Metabolic Disease Clinical Research Committee of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Director of Endocrinology and Metabolism Department,Peking University People's Hospital
14:30 - 14:55
  • 主题报告2
  • Keynote Speech 2
  • 创新药医保准入与支付标准考量要点思考
  • Considerations on Key Points for the Medical Insurance Access and Payment Standards of Innovative Drugs
  • 金春林 上海市卫生和健康发展研究中心主任
  • JIN Chunlin , Director of Shanghai Health Development Research Center
14:55 - 15:20
  • 主题报告3
  • Keynote Speech 3
  • 代谢疾病/减重药物市场趋势与行业分析
  • Trends and Analysis for Metabolic/Anti-Obesity Drugs
  • 贺菊颖 中信建投证券医药行业首席分析师
  • HE Juying , Head of Healthcare Equity Research at China Securities
15:20 - 15:50
  • 主题讨论1
  • Panel 1
  • 如何协同推进代谢药物创新可持续发展
  • How to Advance the Sustainable Development of Innovative Drugs for Metabolic Diseases Through Collaboration
    • Moderator
  • 纪立农 ， 中国药促会糖尿病与代谢性疾病药物临床研究专业委员会主任委员，北京大学人民医院内分泌科主任
  • JI Linong , Chairman of Diabetes and Metabolic Disease Clinical Research Committee of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Director of Endocrinology and Metabolism Department,Peking University People's Hospital
    • Panelists
  • 广州市卫生健康委员会 ， Guangzhou Municipal Health Commission
  • Guangzhou Municipal Health Commission ,
  • 金春林 ， 上海市卫生和健康发展研究中心主任
  • JIN Chunlin , Director of Shanghai Health Development Research Center
  • 朱文静 ， 勃林格殷格翰心肾代谢疾病治疗领域医学负责人
  • Julia ZHU , Therapeutic Area Head of Cardio-Renal-Metabolic diseases in Medicine, Boehringer Ingelheim
  • 袁清慧 ， 中信建投证券制药及生物科技组首席分析师
  • YUAN Qinghui , Head of Pharmaceutical and Biotechnology Industry Equity Research at China Securities
15:50 - 17:40
  • 第二阶段：聚焦热点——肥胖/MASH疾病管理与临床开发趋势
  • Session II: Research Hotspot - Trends in Disease Management and R&D for Obesity/MASH
    • Moderator
  • 姜宏卫 ， 中国药促会糖尿病与代谢性疾病药物临床研究专业委员会委员，河南科技大学第一附属医院副院长
  • JIANG Hongwei , Member of Diabetes and Metabolic Disease Clinical Research Committee of PhIRDA Vice President of the First Affiliated Hospital of Henan University of Science & Technology
15:50 - 16:20
  • 主题报告4
  • Keynote Speech 4
  • 聚焦研发新靶点，审视抗肥胖/MASH药物临床应用前景
  • Focusing on the Progress and Clinical Application Prospects of New Drugs for Obesity and MASH
  • 饶慧瑛 北京大学肝病研究所所长
  • RAO Huiying , Director of Peking University Hepatology Institute
16:20 - 16:45
  • 主题报告5
  • Keynote Speech 5
  • 从基础到临床，探索肥胖症与肝脏疾病密切关联性探讨
  • From Bench to Bed, Exploring the Relationship between Obesity and Fatty Liver Disease
  • 邹显彤 北京大学人民医院副研究员
  • ZOU Xiantong , Assistant Professor of Peking University
16:45 - 17:10
  • 主题报告6
  • Keynote Speech 6
  • 面对代谢疾病临床开发的机遇与挑战
  • The Challenges and Opportunities of Clinical Development for Metabolic Diseases
  • 肖旖旎 勃林格殷格翰(中国)投资有限公司心血管-肾脏-代谢治疗领域临床运营总监
  • Angela XIAO , Cardiovascular-Renal-Metabolic CD&O TAH, Boehringer Ingelheim (China) Investment Co., Ltd.
17:10 - 17:40
  • 主题讨论2
  • Panel 2
  • 如何多方共同优化肥胖/MASH疾病临床开发与疾病管理
  • How to Optimize the Clinical Development and Disease Management of Obesity/MASH Diseases Through Multi-Party Collaboration
    • Moderator
  • 姜宏卫 ， 中国药促会糖尿病与代谢性疾病药物临床研究专业委员会委员，河南科技大学第一附属医院副院长
  • JIANG Hongwei , Member of Diabetes and Metabolic Disease Clinical Research Committee of PhIRDA Vice President of the First Affiliated Hospital of Henan University of Science & Technology
    • Panelists
  • 饶慧瑛 ， 北京大学肝病研究所所长
  • RAO Huiying , Director of Peking University Hepatology Institute
  • 李延兵 ， 中山大学附属第一医院内分泌科主任
  • LI Yanbing , Director of the Department of Endocrinology, First Affiliated Hospital of Sun Yat-sen University
  • 肖旖旎 ， 勃林格殷格翰(中国)投资有限公司心血管-肾脏-代谢治疗领域临床运营总监
  • Angela XIAO , Cardiovascular-Renal-Metabolic CD&O TAH, Boehringer Ingelheim (China) Investment Co., Ltd.